Int J Drug Policy by Ubuguyu, Omary et al.
Improvements in Health-related Quality of Life among 
Methadone Maintenance Clients in Dar es Salaam, Tanzania
Omary Ubuguyu, MD, Mmeda, Olivia C. Tran, MPHb, R. Douglas Bruce, MD, MA, MScc, 
Frank Masao, MD, Mmeda, Cassian Nyandindi, MD, Mmeda, Norman Sabuni, MDd, Sheryl 
McCurdy, PhDe, Jessie Mbwambo, MDa, and Barrot H. Lambdin, PhD, MPHf,g,h
Omary Ubuguyu: oubuguyu@yahoo.com; Olivia C. Tran: ochang@pangaeaglobal.org; R. Douglas Bruce: 
DBruce@cornellscott.org; Frank Masao: drfmasao@yahoo.com; Cassian Nyandindi: cnyandindi@gmail.com; Norman 
Sabuni: drnormansabuni@gmail.com; Sheryl McCurdy: Sheryl.A.McCurdy@uth.tmc.edu; Jessie Mbwambo: 
jmbwambo@gmail.com; Barrot H. Lambdin: blambdin@rti.org
aMuhimbili University of Health and Allied Sciences, PO Box 65001, Dar es Salaam, Tanzania
bPangaea Global AIDS, 436 14th St, Suite 920, Oakland, CA 94612
cYale University, New Haven, CT 06520
dTanzania Ministry of Health and Social Welfare, 6 Samora Machel Ave, Dar es Salaam, Tanzania
eUniversity of Texas School of Public Health, 7000 Fannin St, Houston, TX, USA
fRTI-International, 351 California St, Suite 500, San Francisco, CA 94104
gDepartment of Global Health, University of Washington, Seatttle, WA, USA
hDepartment of Epidemiology and Biostatistics, University of California San Francisco, San 
Francisco, CA, USA, (415) 848-1334
Abstract
Background—Injection of heroin has become widespread in Dar es Salaam, Tanzania and is 
spreading throughout the country. To prevent potential bridging of HIV epidemics, the Tanzanian 
government established a methadone maintenance treatment (MMT) clinic in February 2011. We 
assess the effect of MMT on health-related quality of life (HRQOL) and examine factors, 
particularly HIV infection and methadone dose, associated with changes in HRQOL.
Methods—This study utilized routine data on clients enrolling in methadone from February 2011 
to April 2012 at Muhimbili National Hospital. Change in physical (PCS) and mental health (MCS) 
composite scores, as measured by the SF-12 tool, were the primary outcomes. Backward stepwise 
linear regression, with a criterion of p<0.2 was used to identify baseline exposure variables for 
inclusion in multivariable models, while adjusting for baseline scores.
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Results—A total of 288 MMT clients received baseline and follow-up assessments. Mean 
methadone dose administered was 45 mg (SD±25) and 76(27%) were confirmed HIV-positive. 
Significant improvements were observed in PCS and MCS, with mean increases of 15.7 and 3.3, 
respectively. In multivariable models, clients who had previous poly-substance use with cocaine 
[p=0.040] had a significantly higher mean change in PCS. Clients who were living with HIV 
[p=0.002]; satisfied with current marital situation [p=0.045]; had a history of suicidal thoughts 
[p=0.021]; and previously experienced cognitive difficulties [p=0.012] had significantly lower 
mean change in PCS. Clients with shorter history of heroin use [p=0.012] and who received higher 
methadone doses [p=0.028] had significantly higher mean change in MCS, compared to their 
counterparts.
Discussion—Aspects of mental and physical health, risk behaviors and quality of life among 
drug users are intertwined and complex. Our research revealed positive short-term effects of MMT 
on HRQOL and highlights the importance of sustained retention for optimal benefits. 
Comprehensive supportive services in addition to provision of methadone are needed to address 
the complex health needs of people who inject drugs.
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Background
During the mid-1980s, East Africa became an important drug transit stop, introducing heroin 
in the region. As a consequence, the region also became a point of consumption, with an 
estimated 533,000 opiate users in East Africa (UNODC, 2011). Since the late 1990s, the 
injection of heroin has become widespread in Dar es Salaam, Tanzania and is spreading 
throughout the country (McCurdy, Williams, Kilonzo, Ross, & Leshabari, 2005; Ross, 
McCurdy, Kilonzo, Williams, & Leshabari, 2008; UNODC, 2011). The injection of heroin 
and other illicit substances contributes to the development of acute and chronic medical 
conditions, leading to higher morbidity and mortality (Gupta et al., 2014; Kessler et al., 
2013; Mathers et al., 2013; UNODC, 2013).
People who inject drugs (PWID) in Dar es Salaam have a disproportionately high disease 
burden with an estimated HIV prevalence of 42%–50%, hepatitis C prevalence of 56–76% 
and an active pulmonary TB prevalence of 4%–11% (Gupta et al., 2014; Msami, 2004; 
Nyandindi et al., 2013; Williams et al., 2009). PWID are often socially marginalized and 
face multiple psychiatric co-morbidities (Altice, Kamarulzaman, Soriano, Schechter, & 
Friedland, 2010). Drug users often have lower health-related quality of life (HRQOL), 
especially with regards to mental health conditions when compared to the general population 
or patients with other chronic conditions such as hypertension or diabetes (Deering et al., 
2004; Ryan & White, 1996; Smith & Larson, 2009). More recently, HRQOL has become an 
important outcome in clinical trials and medical interventions for chronic diseases (Osoba, 
2011).
Methadone maintenance treatment (MMT) is one type of treatment for opioid dependence 
and is a component of the comprehensive package of HIV services for people who use 
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opioids (PEPFAR, July 2010). Extensive research supports methadone maintenance as an 
effective treatment for opioid dependence, associated with lowering morbidity and mortality 
and reducing risk behaviors associated with opioid injection (Bruce, 2010; Connock et al., 
2007; Gibson, Flynn, & McCarthy, 1999; JC & A, 1991; Metzger et al., 1993). A systematic 
review examining 13 programs in Asia and Eastern Europe noted significant improvements 
in quality of life, as measured by the WHOQOL-BREF tool, and significant reductions in 
addiction severity over time among participants enrolled in opioid agonist treatment such as 
methadone (Feelemyer, Jarlais, Arasteh, Phillips, & Hagan, 2013).
In response to the emerging injection drug use crisis, the government of Tanzania established 
the first publicly funded MMT clinic on the mainland of sub-Saharan Africa. We 
hypothesized that MMT is associated with improvements in HRQOL but differential 
improvements would be observed based on baseline risk factors. We conducted a 
retrospective cohort study to understand the effect of MMT on health-related quality of life 
and factors associated with changes in HRQOL over time. To our knowledge, this is one of 
the first studies examining HRQOL among methadone clients in sub-Saharan Africa.
Methods
Study Setting
In February 2011, the Tanzania AIDS Prevention Project launched the first MMT clinic in 
Tanzania, offering methadone, at Muhimbili National Hospital in Dar es Salaam. The 
establishment of methadone services was supported by the Tanzanian government – namely, 
the Ministry of Health and Social Welfare and Drug Control Commission – as well as the 
U.S. Centers for Disease Control and Prevention (CDC), Muhimbili University of Health 
and Allied Sciences, and Pangaea Global AIDS (Pangaea). The methadone program has 
been previously described in detail (Bruce et al., 2014; Gupta et al., 2014; Barrot H Lambdin 
et al., 2013; B. H. Lambdin et al., 2014; Tran et al., 2015). Briefly, the clinic provides 
methadone to clients seven days a week by direct observation and offers integrated services 
such as counseling and testing for HIV and hepatitis, tuberculosis testing and daily observed 
treatment, mental health, and psychosocial support (Bruce et al., 2014).
Study Population
Study subjects included 288 clients of the 419 (69%) who enrolled into the methadone 
program from February 2011 to April 2012 at Muhimbili National Hospital and met the 
below criteria. Inclusion criteria for methadone initiation included: 1) opioid dependence, 2) 
evidence of recent drug injection, and 3) positive opiate urine screening. Other additional 
study criteria included: 1) 18 years of age or older, 2) complete baseline data collection 
within one week of enrollment and 3) a completed follow-up assessment 3 to 6 months post 
enrollment into the methadone program.
Data Sources
The study utilized the electronic database at the MMT clinic at Muhimbili National 
Hospital. As part of routine care, MMT clients were asked to complete a comprehensive 
baseline survey to collect demographic, drug history, legal history, mental health (depression 
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and anxiety), and HIV risk behavior data. The survey also included the health-related quality 
of life tool (SF-12) (Ware, Kosinski, & Keller, 1996)which has been previously used and 
validated in the Tanzanian context (Atkinson, Mccurdy, Williams, Mbwambo, & Kilonzo, 
2011; Kaaya et al., 2002; Lee, Kaaya, Mbwambo, Smith-Fawzi, & Leshabari, 2008; Magafu 
et al., 2009; Wagner et al., 1999; Wyss et al., 1999). The follow-up survey contained the 
same components and was completed between three to six months after baseline.
Measures
Exposures—Patient-level characteristics were extracted from the MMT electronic 
database. Demographic factors included age (≤25, 26–35, ≥36);sex (male/female); education 
level (primary schooling or lower); current marital status (married/unmarried); parental 
status (has children/does not have children); current employment status (formally employed/
unemployed); and baseline HIV status (positive or negative result within 90 days of 
methadone enrollment). Drug-use history factors included length of heroin use (in years) and 
poly-substance use (heroin with alcohol, cocaine, or benzodiazepine). Injection-related risk 
behaviors, mental health domains and history of abuse were analyzed as dichotomous 
exposure variables (yes/no). Injection-related risk behaviors included “flashblood” (injecting 
blood from another drug user who has recently injected heroin) (McCurdy, Ross, Williams, 
Kilonzo, & Leshabari, 2010); sharing needles at last injection; and sharing other equipment 
at last injection. Mental health domains included high substance dependence (defined as 
having the maximum score of a 7-point scale) ((APA), 2000); depression in the last 30 days; 
anxiety in the last 30 days; a history of suicidal thoughts or attempts; hallucinations (visual 
or auditory); cognitive difficulties with understanding, concentrating, or remembering; 
violent behavior; satisfaction with current marital status; and satisfaction with current living 
situation. History of abuse was characterized as any self-reported history of physical abuse 
or sexual abuse. MMT-associated treatment factors included average daily dose during the 
first three months of treatment. Methadone dose was categorized into above (≥85 mg) and 
below (<85 mg), based on a Cochrane review of methadone dosing and previous research 
among this client population (Brady et al., 2005; Fareed, Casarella, Amar, Vayalapalli, & 
Drexler, 2010; B. H. Lambdin et al., 2014; Mattick, Kimber, Breen, & Davoli, 2008; Tran et 
al., 2015).
Outcomes—Change in health-related quality of life, as measured by the SF-12 tool (v1)
(Ware et al., 1996; Ware, Snow, Kosinski, & Gandek, 1995) was the primary outcome of 
interest. The tool included all 12 questions that measure functional health and well-being 
from the patient’s point-of-view. The SF-12 has been extensively validated, is well-accepted 
by patients, and performs well across diverse population groups. In particular, SF-12 has 
demonstrated excellent reliability and validity in the general population (Ware et al., 1996); 
among individuals with severe mental illness and substance dependence (Salyers, Bosworth, 
Swanson, Lamb-Pagone, & Osher, 2000); and among people living with HIV 
(Chariyalertsak et al., 2011; Delate & Coons, 2000; Han, Pulling, Telke, & Huppler 
Hullsiek, 2002; Viswanathan, Anderson, & Thomas, 2005; Wu, Hays, Kelly, Malitz, & 
Bozzette, 1997). The use of the SF-36, from which the SF-12 is based, has also 
demonstrated validity in Tanzania (Magafu et al., 2009; Wagner et al., 1999; Wyss et al., 
1999). Data were collected at baseline and at three to six months follow-up and extracted 
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from the MMT electronic database for analysis. Overall Physical and Mental Health 
Composite Scores (PCS and MCS, respectively) at baseline and follow-up were computed 
according to standard protocol (Ware et al., 1995). Then, the change in scores between 
baseline and follow-up was calculated for each composite.
Statistical Methods
Paired Student T–tests were used to examine differences between mean HRQOL scores of 
participants before and after initiation of methadone treatment.
Multivariable linear regression with robust standard errors was used to identify independent 
baseline predictors of HRQOL changes. Backward stepwise regression with a p-value of 0.2 
was used to select variables for inclusion in the final multivariable model. All analyses were 
adjusted for baseline composite scores. Throughout this study two-tailed p-values, with p<.
05 were considered to be statistically significant. All statistical analyses were conducted 
using Stata 12.1 (College Station, TX).
Ethical Considerations
Ethical clearance was granted by Muhimbili University of Health and Allied Sciences 
(MUHAS) Research and Publication Committee in Dar es Salaam, Tanzania. The use and 
analysis of de-identified, programmatic data was also approved by the U.S. Centers for 
Disease Control and Prevention, E&I Review Services in the United States as program 
evaluation and non-human subjects research.
Results
MMT Clients
A total of 288 MMT clients were included in this study. Baseline characteristics of enrolled 
patients are presented in Table 1. Overall, 260 (90%) were male; 162(56%) had primary 
education or lower; 93 (32%) had children; 36 (13%) were married, and 238 (83%) were 
unemployed. Median length of heroin use was 10 years (IQR: 6, 15) and 5 (2%), 65 (22%) 
and 39 (14%) reported poly-substance use with cocaine, alcohol, benzodiazepine, 
respectively.
Improvements in HRQOL
At baseline, mean overall Physical and Mental Health Composite Scores were 37.9 (95% CI: 
36.7, 39.0) and 38.4 (95% CI: 37.5, 39.3), respectively. Significant improvements in both 
scores between baseline and follow-up were observed (p<0.001). At follow-up, PCS scores 
made a large improvement, increasing by an average of 15.7 points to 53.6 (95% CI: 52.6, 
54.6) and MCS scores made a small to medium improvement, increasing by an average of 
3.3 points to 41.7 (95% CI: 40.1, 42.4).
Predictors of Changes in HRQOL
Table 2 shows the associations of baseline characteristics with changes in PCS in univariate 
and multivariable models. In the adjusted model, MMT clients who had previous poly-
substance use with cocaine [p=0.040] had a significantly higher mean change in PCS. 
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Patients who were living with HIV [p=0.002]; satisfied with their current marital situation 
[p=0.045], had a history of suicidal thoughts [p=0.021], and had previously experienced 
cognitive difficulties [p=0.012] had significantly lower mean change in physical component 
scores as compared to their counterparts.
Table 3 presents results of univariate and multivariable linear regression models of the 
associations of baseline characteristics with changes in Mental Health Composite Scores. In 
the adjusted model, MMT clients who had a longer history of heroin use had significantly 
lower mean change in mental health composite score, compared to clients who had a shorter 
history of heroin use [p=0.012], and people with a higher methadone dose at initiation had a 
significantly higher mean change in mental health composite score, compared to people with 
a lower methadone dose at initiation [p=0.028].
Discussion
Utilizing data from the first publicly funded methadone clinic on the mainland of Sub-
Saharan Africa, this study compared HRQOL among PWID prior to and three to six months 
after MMT initiation and examined factors associated with changes in HRQOL. Consistent 
with research documenting the impact of MMT on quality of life (Feelemyer et al., 2013), 
we observed significant short-term improvements in HRQOL, on average, in the first cohort 
of opioid addicts receiving MMT in Tanzania. Longer duration on methadone may lead to 
even larger improvements in HRQOL and future analyses will attempt to examine long term, 
sustained changes in HRQOL.
Greater improvements were seen in PCS than MCS, suggesting that methadone may have 
more immediate effects on physical health than mental health. Despite significant 
improvements, follow-up physical and mental health composite scores remained below those 
observed in other patient populations throughout Africa, such as hypertensive patients 
(Ogunlana, Adedokun, Dairo, & Odunaiya, 2009); persons living with HIV (Mbada, 
Onayemi, Ogunmoyole, Johnson, & Akosile, 2013); and survivors of critical illness 
(Schneiderman, 2012). Although specific etiologies for the differences remain to be 
determined, many of the substance users in this cohort have experienced more negative 
effects on quality of life before starting methadone and have co-occurring mental health 
disorders requiring more than three to six months to properly address, as compared to 
patients who struggle with hypertension.
Significantly higher mean changes in PCS were observed among those who had previous 
poly-substance use with cocaine. In contrast, significantly lower mean changes in PCS were 
observed among clients who were living with HIV, satisfied with their current marital 
situation, had a history of suicidal thoughts, and had previous difficulty with understanding, 
concentrating or remembering things. Clients with shorter history of heroin use had 
significantly higher mean changes in MCS. Surprisingly, no baseline mental health 
characteristics were associated with change in MCS.
Concomitant use of heroin and cocaine has severe health and social consequences and can 
undermine the effectiveness of medication-assisted treatment (Condelli, Fairbank, Dennis, & 
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Rachal, 1991; Grella, Anglin, & Wugalter, 1997; F. Leri, Bruneau, & Stewart, 2003). 
Behavioral interventions such as substance abuse counseling and urine screening were 
implemented to address concurrent cocaine use. It is important to note that only a small 
proportion of clients reported concurrent cocaine use in the 30 days prior to methadone 
initiation (2%). When adjusted for other potentially confounding factors, MMT clients who 
reported previously using cocaine experienced significant improvements in physical health. 
Heroin and cocaine co-use has been documented in anecdotal and clinical evidence 
elsewhere, but the neurobiological mechanisms associated with co-use are not clearly 
understood (F. Leri et al., 2003; Francesco Leri et al., 2005). Prior research suggests that 
cocaine may alleviate some opioid withdrawal symptoms and that the subjective effects of 
cocaine are enhanced in opioid-dependent individuals. However, additional research is 
needed to fully understand the neurobiological effects of combined heroin and cocaine use 
and underlying factors associated with co-use and how those in turn affect quality of life.
Previous research indicates that marital status and social support are associated with better 
overall health and improved outcomes in drug users and hospitalized or chronically ill 
individuals (De Maeyer, Vanderplasschen, & Broekaert, 2009; DiMatteo, 2004; Dobkin, De, 
Paraherakis, & Gill, 2002; Kiecolt-Glaser & Newton, 2001; Nuwaha & Musinguzi, 2013; 
Preau et al., 2007; Rhoads, 1983). However, also important is the level of satisfaction with 
one’s current situation (Kiecolt-Glaser & Newton, 2001). Satisfaction with current marital 
status was 83% among married individuals and only 39% for single or unmarried 
participants (data not shown). Satisfaction with current marital status was associated with 
higher baseline PCS scores (data not shown) in our cohort. However, when adjusted for 
other baseline factors, it was associated with lower mean change in physical health. These 
findings warrant additional investigation on the effects of marital status, personal 
relationships and social support on HRQOL and the physiological pathways between marital 
relationships to health outcomes.
Mental illness impacts quality of life, substance use severity, adherence to treatment, and 
overall success of treatment (Alonso et al., 2004; Brooner, King, Kidorf, Schmidt, & 
Bigelow, 2015; Evans, Banerjee, Leese, & Huxley, 2007). People who inject drugs often 
have comorbid psychiatric conditions that lead to impaired functioning and decreased well-
being (Darke, Swift, & Hall; Kendler, Prescott, Myers, & Neale, 2003). This was apparent in 
our study population, in which 26% reported experiencing serious depression in the previous 
30 days; 26% experienced serious anxiety in the last 30 days; 22% reported difficulty with 
understanding, concentrating or remembering; and 14% experienced visual or auditory 
hallucinations.
Attempted suicide and suicidal ideations present a significant clinical challenge in 
methadone maintenance programs, distinct from heroin overdose. Previous studies have also 
shown that substance abuse is one of the biggest risk factors for suicide risk (Borges et al., 
2006; Harris & Barraclough, 1997; Joe, Stein, Seedat, Herman, & Williams, 2008; Wilcox, 
Conner, & Caine, 2004). Additional risk factors, including extensive polysubstance use, 
major depression, perceptions of belonging and burdensomeness, and sexual or physical 
victimization, are associated with higher risk of suicide and suicidal ideations among drug 
users (Bohnert, Roeder, & Ilgen, 2011; CSAT, 2008; Farrell, Neeleman, Griffiths, & Strang, 
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1996; Ilgen et al., 2010; Roy, 2001). In our study population, 10% of participants reported 
having suicidal thoughts and 3% had attempted suicide in the past. The enduring detrimental 
effect of mental health disorders, particularly suicidal thoughts, on the physical component 
score, was observed among methadone clients. These findings reinforce the critical need for 
a comprehensive approach to provide routine mental illness screenings, increased suicide 
risk assessment and appropriate treatment to address co-occurring conditions. In addition to 
diagnosis and treatment, an approach must focus equally on prevention.
Aspects of mental and physical health, risk behaviors and quality of life among drug users 
are intertwined and complex. In addition to improving HRQOL, retention in methadone can 
lead to reductions in HIV risk behaviors, less HIV transmission into the community, and 
improved adherence to HIV and TB medications, thereby reducing morbidity and mortality. 
In particular, methadone dose has been a critical factor in retaining clients in treatment and 
linking clients into additional health services (Bao et al., 2009; Sarasvita, Tonkin, Utomo, & 
Ali, 2012; Tran et al., 2015; Wang et al., 2012). Higher dosing of methadone is known to 
suppress withdrawal symptoms and provide greater opioid blocking abilities should heroin 
be ingested (Donny, Brasser, Bigelow, Stitzer, & Walsh, 2005; Donny, Walsh, Bigelow, 
Eissenberg, & Stitzer, 2002). Similar to other studies, higher doses of methadone were 
associated with significant short-term improvements in quality of life among out study 
cohort (Wang et al., 2012). It is important to keep in mind that individuals suffering from 
high substance dependence and/or with a long history of substance use are often initiated on 
higher doses of methadone.
Strengths of this study included the use of standardized clinical protocols and routine data 
sources. However, the study should be interpreted in light of some important limitations. 
Clients who dropped out of methadone treatment missed follow-up data limited the number 
of individuals included in the study. Due to limited sample size, we were unable to 
adequately examine interactions between baseline characteristics and HRQOL. In addition, 
the SF-12 allows calculation of only the summary scales for physical and mental health and 
not the subscales, which may contain other valuable information. Other limitations of this 
research included its observational nature and potential for unmeasured or mismeasured 
covariates to bias our results. In addition to examining statistical significance, it will be 
important to evaluate the magnitude of changes to establish the minimally important 
difference in HRQOL. This was not the primary focus of this study, but researchers hope 
that these data can help inform the growing field.
In conclusion, this study demonstrated the positive short-term effects of methadone 
treatment on health-related quality of life and highlights the importance of sustained 
retention in treatment for optimal benefits. However, comprehensive supportive services in 
addition to provision of methadone are needed to address the complex health needs of 
PWID. Regular screenings and health monitoring, with a focus on both prevention and 
treatment, among clients receiving methadone are fundamental to improving quality of life. 
Future research should examine the long-term effects of methadone on HRQOL.
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Table 2
Univariate and Multivariable Regression Coefficients for Changes in Physical Health Composite Score
Univariate Regression Coefficient (95% 
CI) p-value
Multivariable Regression 




 26–35 3.76 (−2.34, 9.86) 0.636*
 36–45 3.51 (−2.92, 9.95)
Male 4.14 (−0.32, 8.59) 0.069
Married −0.76 (−5.79, 4.27) 0.766
At least one child 1.2 (−1.82, 4.22) 0.435
Primary Level Education or Lower −1.53 (−4.45, 1.38) 0.302
Unemployed 2.36 (−1.10, 5.82) 0.18
Satisfied with current living arrangements −2.95 (−5.78, −0.12) 0.04
HIV-positive −4.57 (−8.02, −1.13) 0.009 −3.84 (−6.27, 1.41) 0.002
Drug Use History
Years of heroin use −0.03 (−0.28, 0.22) 0.808
Polysubstance Use (last 30d)
 Cocaine 9.03 (1.03, 17.03) 0.027 3.37 (0.16, 6.59) 0.040
 Alcohol 0.41 (−3.02, 3.85) 0.813
 Benzodiazepine 2.17 (−2.0, 6.34) 0.307
Sexual Risk Factors
Multiple Sex Partners (last 6m) −2.02 (−6.02, 1.99) 0.323
Risky Sexual Behavior (last 6m) −0.65 (−3.57, 2.28) 0.665
Injection Risk Factors
Ever Used Flashblood −1.87 (−6.83, 3.08) 0.458
Shared Needles at Last Injection −2.37 (−7.13, 2.40) 0.329
Shared other Equipment at Last Injection −1.11 (−5.45, 3.23) 0.614
Mental Health History
Depression in Last 30 Days 1.58 (−1.91, 5.08) 0.373
Anxiety in Last 30 Days 1.24 (−2.20, 4.68) 0.479
Ever had Suicidal Thoughts −2.42 (−8.08, 3.23) 0.4 −5.35 (−9.88, −0.82) 0.021
Ever Attempted Suicide −5.98 (−18.93, 6.97) 0.364
Ever experienced hallucinations 2.58 (−1.78, 6.94) 0.245 3.21 (−0.08, 6.50) 0.056
Cognitive difficulties 1.13 (−2.82, 5.07) 0.575 −4.29 (−7.64, −0.94) 0.012
Trouble controlling aggression 3.46 (−2.74, 9.65) 0.273
Previous psychiatric treatment −0.06 (−11.22, 11.11) 0.992
Satisfied with current marital status −4.73 (−7.63, −1.84) 0.001 −2.13 (−4.20, −0.05) 0.045
History of Abuse
Any History of Physical Abuse 2.44 (−1.68, 6.57) 0.245
Any History of Sexual Abuse −6.07 (−17.37, 5.22) 0.291
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Univariate Regression Coefficient (95% 
CI) p-value
Multivariable Regression 
Coefficient (95% CI) p-value
Criminal History
Ever arrested 3.32 (0.56, 6.17) 0.023
Methadone Dose at Initiation
 ≥85 mg 1.40 (−2.48, 5.30) 0.478
*
test from group-linear term
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Table 3
Univariate and Multiariable Regression Coefficients for Changes in Mental Health Composite Score
Univariate Regression Coefficient 
(95% CI) p-value
Multivariable Regression 




 26–35 −0.005 (−4.76, 4.75) 0.002*
 36–45 −4.07 (−9.02, 0.88)
Male 0.1 (−3.76, 3.95) 0.96
Married −0.62 (−4.18, 2.93) 0.731
At least one child −1.05 (−3.45, 1.35) 0.391
Primary Level Education or Lower 1.38 (−0.9, 3.66) 0.235 1.04 (−0.50, 2.58) 0.184
Unemployed 0.97 (−1.88, 3.83) 0.503
Satisfied with current living arrangements 0.41 (−1.90, 2.72) 0.725
HIV-positive −0.32 (−2.82, 2.17) 0.8
Drug Use History
Years of heroin use −0.15 (−0.62, 0.23) 0.088 −0.16 (−0.30, −0.04) 0.012
Polysubstance Use in Last 30 days
 Cocaine 8.64 (−0.08, 17.36) 0.05
 Alcohol −0.03 (−2.79, 2.73) 0.983
 Benzodiazepine −1.13 (−4.48, 2.22) 0.506
Sexual Risk Factors
Multiple Sex Partners in Last Six Months −1.1 (−4.14, 1.95) 0.479
Risky Sexual Behavior in Last Six Months 0.74 (−1.56, 3.04) 0.528
Injection Risk Factors
Ever Used Flashblood 0.55 (−3.18, 4.28) 0.771
Shared Needles at Last Injection 2.59 (−0.47, 5.64) 0.096
Shared other Equipment at Last Injection 1.89 (−1.52, 5.31) 0.276
Mental Health History
Depression in Last 30 Days −0.09 (−2.49, 2.31) 0.941
Anxiety in Last 30 Days −0.65 (−3.04, 1.75) 0.596
Ever had Suicidal Thoughts 0.58 (−2.64, 3.80) 0.723
Ever Attempted Suicide 2.56 (−4.33, 9.45) 0.466
Ever experienced hallucinations 0.57 (−2.25, 3.40) 0.69
Cognitive difficulties −1.41 (−3.96, 1.13) 0.276
Trouble controlling aggression 2.6 (−1.08, 6.27) 0.165 2.14 (−0.57, 4.84) 0.121
Previous psychiatric treatment 2.68 (−3.51, 8.88) 0.395 1.86 (−0.49, 4.21) 0.120
Satisfied with current marital status −0.69 (−2.96, 1.59) 0.553
History of Abuse
Any History of Physical Abuse 0.56 (−2.76, 3.87) 0.741
Any History of Sexual Abuse 1.2 (−4.45, 6.86) 0.676
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Univariate Regression Coefficient 
(95% CI) p-value
Multivariable Regression 
Coefficient (95% CI) p-value
Criminal History
Ever arrested 0.17 (−2.19, 2.54) 0.886
Methadone Dose at Initiation
 ≥85 mg 2.18 (−1.59, 5.95) 0.257 1.65 (0.17, 3.13) 0.028
*
test from group-linear term
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